In Vitro Toxicology Testing Market

In Vitro Toxicology Testing Market by Product (Assays (Western Blot, Tissue Culture), Equipment, Consumables, Software), Toxicity Endpoints (ADME, Skin Irritation, Cytotoxicity), Technology, Method, Industry (Pharma,Biotech) - Global Forecast to 2027

Report Code: BT 2373 Jun, 2022, by marketsandmarkets.com

[370 Pages Report] The in vitro toxicology testing market is expected to reach USD 18.6 billion by 2027 from an estimated USD 11.2 billion in 2022, at a CAGR of 10.8%. Factors such as technological advancements, opposition to animal testing, and increasing R&D expenditure to detect toxicity at an early stage during drug development drive market growth.

In Vitro Toxicology Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global In Vitro Toxicology Testing Market

The in vitro toxicology market is expected to grow at an approximately CAGR of 11.0%-13.0% for next two years according to our analysis. The below factors are playing a key role in advancement of the growth of the global market.

  • The demand for in vitro toxicology technologies has increased, especially diagnostic assays and PCR equipment’s, due to the increase in demand for faster testing and research being conducted in the field.
  • Globally, the outbreak of COVID-19 has been increasing at an exponential level. This has led to a decline in the number of profiling studies being conducted under normal circumstances. This is expected to inhibit market growth to a certain extent.

In Vitro Toxicology Testing Market Dynamics

How growth of toxicology testing closely related to R&D spend of pharma companies?

Drug development is always associated with the highest risk of failure in the later stages, where the capital at stake is also huge. Toxicity accounts for ~30% of expensive, late-stage failures in drug development and market withdrawal, which may result in a high attrition rate during the late stages of the pharmaceutical drug discovery process. One estimate is that for every 10,000 compounds synthesized in the discovery phase, only 250 will reach the preclinical phase, ultimately resulting in one approved drug by the FDA (Source: NCBI--National Center for Biotechnology Information). Therefore, to lower the risk of the same, it is very important to identify and prioritize efforts to bring the attrition of failing molecules to an earlier stage in drug development. According to the IFPMA (2019), the R&D expenditure of pharmaceutical companies around the globe was USD 165 billion in 2017. The pharmaceutical and biotechnology industries top the list of R&D investments for any industry, with the EU accounting for the major share of investment in R&D followed by the US, Japan, and China. An increase in R&D investments in the initial stages is expected to drive the use of in vitro toxicity methods before the drug reaches the more expensive preclinical and clinical stages.

Why is lack of in vitro models a critical restraining factor that is holding back growth of market?

Autoimmunity and immune stimulation are important endpoints because half the new drugs developed are human proteins and antibodies. Currently, these therapeutic molecules can be tested only in animal models. In vitro testing methods do not allow the evaluation of the memory response triggered inside a body, post a secondary infection. In vitro methods lack the ability to evaluate the recovery response of a body with respect to acute versus long-term immunosuppression. It also cannot evaluate the toxic effects on lymphoid architecture, such as on lymph nodes, which could lead to defects in cellular interactions necessary for the induction of immune response. Currently, there are no good systems for in vitro antibody production using human cells, unlike T-dependent antibody SRBC (sheep red blood cells) in animals. Due to the lack of in vitro models, guidelines still depend on animal tests to detect autoimmunity and immune stimulation.

For instance, developmental toxicity is one of the most animal-intensive areas of regulatory toxicology. Although there are in vitro methods to test developmental toxicity, none of them determine the potential adverse outcomes needed to assure safety. For genotoxicity, most regulatory authorities and international agencies recommend an in vivo test along with in vitro tests. In neurotoxicity testing, the difficulty in designing an in vitro test is due to the complexity of cellular and mechanistic processes, which have not been fully identified. Although in vitro tests for neurotoxicity are available, none of them have been reviewed or validated by regulatory authorities. Thus, the lack of validated in vitro models to study the complex mechanisms and evaluate the toxicity potential of drugs is a major factor expected to restrain the growth of the market.

What opportunities does increase in toxicology databases open up for companies?

The need for speeding up the toxicological assessment of chemicals and using fewer animals and less-expensive tools has strongly stimulated the development of predictive toxicology and structure-based approaches. To make predictive toxicology methods more effective, the field needs access to the largest possible knowledge base of previous toxicology findings, which also needs to be interoperable and comparable. Databases with records of safety profiles of chemicals, their mode of actions, genetic implications, lethal dose information, different formulations, and toxicogenomic information will help promote the efficient use of alternative methods of toxicology testing. These databases will also reduce the repetition of toxicity tests for the same chemicals for safety assessment, ultimately reducing the use of animals for testing. Contributing and sharing data on a common platform will help in understanding the different aspects of toxic substances and the effects of it on a living system. Thus, the development of open, public, and computable toxicology datasets based on standardized and controlled vocabularies will support data management, model building, integrated analysis, validation, and reporting, including regulatory reporting and alternative testing submission requirements, leading to new scientific advances in a mechanistically based predictive toxicology. This will contribute to the growth of the market.

How is dearth of skilled professionals impacting growth of the market?

There is a need for highly skilled personnel for method development, validation, operation, and troubleshooting activities. It involves labor-intensive techniques to perform experiments and requires skilled professionals such as technicians and researchers to set up and run tests and experiments, make observations, obtain results, and analyze data. A lack of knowledge regarding the underlying scientific principles may result in several direct and indirect expenses and, thereby, increase the workload and time pressure on researchers and service providers.

In 2021, the consumables segment is expected to account for the largest share of the in vitro toxicology testing market

The large share of the consumables segment in the market can be attributed to repeated use of media and reagents in vitro toxicology studies and increasing demand for high-quality reagents, this has led consumables to be the largest revenue contributor to the market in 2021.

The organ toxicity segment is expected to grow at a high CAGR during the forecast period

The toxicity endpoints and tests market, includes corrosion, and sensitization; genotoxicity; cytotoxicity; ocular toxicity; organ toxicity; phototoxicity; dermal toxicity; ADME; skin irritation; and other endpoints & tests. During the forecast period, the organ toxicity segment is expected to grow at the highest CAGR.

In 2021, the cell culture technologies segment is expected to account for the largest share of the in vitro toxicology technologies market

In 2021, the cell culture technologies segment accounted for the largest share of the market. Cell culture technologies is the most preferred technique for toxicity testing.

In Vitro Toxicology Testing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Asia Pacific is expected to grow at the highest rate in the in vitro toxicology testing market in 2021

The market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. This is due to the opposition to animal testing resulting in the use of alternate methods, emergence of CROs, growing consumer awareness of product safety, and increasing pharmaceutical drug pipeline, all of which are driving adoption of in vitro toxicology testing in the Asia Pacific.

Key Market Players

The prominent players in the in vitro toxicology testing market include Thermo Fisher Scientific, Inc. (US), Laboratory Corporation of America Holdings (US), Bio-Rad Laboratories, Inc. (US), General Electric Company (US), Eurofins Scientific (Luxembourg), Merck KGaA (Germany), Charles River Laboratories International, Inc. (US), Catalent, Inc. (US), Evotec (UK), SGS S.A. (Switzerland), QIAGEN (Germany), Promega Corporation (US), Gentronix Limited (UK), BioIVT (US), and MB Research Laboratories (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Product & Service, Technology, Toxicity Endpoint & Test, Industry, Method, and Region

Geographies covered

North America, Europe, APAC, Latin America, and the Middle East & Africa

Companies covered

Thermo Fisher Scientific, Inc. (US), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Bio-Rad Laboratories, Inc. (US), General Electric Company (US), Merck KGaA (Germany), Charles River Laboratories International, Inc. (US), Catalent, Inc. (US), Evotec (UK), SGS S.A. (Switzerland), BioRad Laboratories, QIAGEN (Germany), Promega Corporation (US), Gentronix Limited (UK), BioIVT (US), MB Research Laboratories (US), Creative Biolabs(US), GVK Biosciences Private Limited (India), Shanghai Medicon Inc (China), Creative Biorray (US) and Insphero (Switzerland).

In Vitro Toxicity Testing Market, by Product & Service

  • Covid Impact,By Product & Service
  • Consumables
  • Assays
    • Bacterial Toxicity Assays
    • Enzyme Toxicity Assays
    • Cell-based Elisa & Western Blots
    • Receptor-binding Assays
    • Tissue Culture Assays
    • Other Assays
  • Equipment
  • Software
  • Services

In Vitro Toxicity Testing Market, by Method

In Vitro Toxicity Testing Market, by Toxicity Endpoint & Test

  • ADME
  • Skin Irritation, Corrosion, & Sensitization
  • Genotoxicity Testing
  • Cytotoxicity Testing
  • Ocular Toxicity
  • Organ Toxicity
  • Phototoxicity Testing
  • Dermal Toxicity
  • Other Toxicity Endpoints & Tests

In Vitro Toxicity Testing Market, by Industry

  • Covid Impact,By Industry
  • Pharmaceuticals & Biopharmaceuticals
  • Cosmetic & Household Products
  • Food
  • Chemicals

In Vitro Toxicity Testing Market, by Technology

  • Cell Culture Technologies 
  • High-throughput Technologies 
  • Toxicogenomics

In Vitro Toxicity Testing Market, by Region

  • Covid Impact,By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of APAC
  • Latin America
  • Middle East & Africa

Recent Developments

  • In March 2022, Laboratory Corporation of America Holdings acquired AtlantiCare diagnostic clinical laboratory services.
  • In September 2021, Laboratory Corporation of America Holdings Acquired Myriad Autoimmune’s Vectra Testing Business, autoimmune business unit, including the Vectra rheumatoid arthritis (RA) assay.
  • In August 2020, Merck KGaA acquired BSSN Software, a German laboratory informatics company, for ease of data integration, collaboration, analysis, and long-term archiving in laboratories.
  • In April 2019, Charles River Laboratories acquired Citoxlab, a non-clinical CRO, for USD 494 million (EUR 448 million).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 44)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
           1.2.2 MARKETS COVERED
                    FIGURE 1 IN VITRO TOXICOLOGY TESTING MARKET
                    FIGURE 2 GLOBAL MARKET: GEOGRAPHIC SCOPE
           1.2.3 YEARS CONSIDERED FOR STUDY
    1.3 CURRENCY
    1.4 STAKEHOLDERS
    1.5 LIMITATIONS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 49)
    2.1 RESEARCH APPROACH
           FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Breakdown of primaries
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION & VALIDATION APPROACH
           FIGURE 5 MARKET SIZE APPROACH
           FIGURE 6 BOTTOM-UP APPROACH
    2.3 DATA TRIANGULATION APPROACH
           FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR STUDY

3 EXECUTIVE SUMMARY (Page No. - 57)
    FIGURE 8 IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 GLOBAL MARKET, BY TOXICITY ENDPOINT & TEST, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 GLOBAL MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 GLOBAL TING MARKET, BY INDUSTRY, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 GLOBAL MARKET, BY METHOD, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 GEOGRAPHIC ANALYSIS: GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 62)
    4.1 IN VITRO TOXICOLOGY TESTING MARKET OVERVIEW
           FIGURE 14 OPPOSITION TO ANIMAL TESTING IS MAJOR FACTOR DRIVING MARKET GROWTH
    4.2 ASIA PACIFIC: MARKET, BY METHOD
           FIGURE 15 CELLULAR ASSAYS HELD LARGEST SHARE OF GLOBAL MARKET IN ASIA PACIFIC IN 2021
    4.3 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 16 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL MARKET DURING FORECAST PERIOD
    4.4 IN VITRO TOXICOLOGY TESTING MARKET, BY REGION
           FIGURE 17 EUROPE WILL CONTINUE TO DOMINATE GLOBAL MARKET IN 2027
    4.5 GLOBAL MARKET: DEVELOPED VS. DEVELOPING MARKETS
           FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER CAGR THAN DEVELOPED MARKETS THROUGHOUT FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 66)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 19 IN VITRO TOXICOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Public opposition to animal testing
                    5.2.1.2 Technological advancements in toxicology
                    5.2.1.3 R&D on early-stage toxicity detection
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 Reluctance of some regulatory authorities to adopt alternative toxicology testing methods
                    5.2.2.2 Failure to establish intricacies of in-vivo conditions
                    5.2.2.3 Lack of in vitro models to study complex endpoints
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Growing focus on drug discovery and personalized medicine using in vitro methods
                    5.2.3.2 Increasing number of toxicology databases
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Dearth of skilled professionals in toxicity testing

6 INDUSTRY INSIGHTS (Page No. - 72)
    6.1 INTRODUCTION
    6.2 INDUSTRY TRENDS
           6.2.1 INCREASING FOCUS ON PREDICTIVE TOXICOLOGY
    6.3 SUPPLY CHAIN ANALYSIS
           FIGURE 20 SUPPLY CHAIN ANALYSIS: IN VITRO TOXICOLOGY TESTING MARKET
    6.4 REGULATORY COMMITTEE ACTIVITIES
           6.4.1 MAJOR STAKEHOLDERS
           6.4.2 KEY INFLUENCERS
    6.5 COVID-19 IMPACT ON IN VITRO TOXICOLOGY MARKET
           FIGURE 21 IMPACT OF COVID-19 ON GLOBAL MARKET
    6.6 PORTER’S FIVE FORCES ANALYSIS
           TABLE 1 PORTER’S FIVE FORCES ANALYSIS
           6.6.1 THREAT OF NEW ENTRANTS
           6.6.2 THREAT OF SUBSTITUTES
           6.6.3 BARGAINING POWER OF SUPPLIERS
           6.6.4 DEGREE OF COMPETITIVE RIVALRY
    6.7 TECHNOLOGY ANALYSIS

7 IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE (Page No. - 79)
    7.1 INTRODUCTION
    7.2 COVID-19 IMPACT, BY PRODUCT & SERVICE
           FIGURE 22 CONSUMABLES TO CAPTURE MAJORITY OF MARKET SHARE IN 2022
           TABLE 2 GLOBAL MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
           TABLE 3 GLOBAL MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
    7.3 CONSUMABLES
           7.3.1 CONSUMABLES TO ACCOUNT FOR LARGER MARKET SHARE THAN OTHER PRODUCTS IN 2022
                    TABLE 4 IN VITRO TOXICOLOGY TESTING CONSUMABLES MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 5 IN VITRO TOXICOLOGY TESTING CONSUMABLES MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    7.4 ASSAYS
           TABLE 6 ASSAYS: IN VITRO TOXICOLOGY TESTING MARKET, BY TYPE, 2019–2021 (USD MILLION)
           TABLE 7 ASSAYS: MARKET, BY TYPE, 2022–2027 (USD MILLION)
           TABLE 8 ASSAYS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
           TABLE 9 ASSAYS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
           7.4.1 BACTERIAL TOXICITY ASSAYS
                    7.4.1.1 Bacterial assays to capture largest market share in coming years owing to their increasing adoption across several industries
                               TABLE 10 BACTERIAL TOXICITY ASSAYS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                               TABLE 11 BACTERIAL TOXICITY ASSAYS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
           7.4.2 ENZYME TOXICITY ASSAYS
                    7.4.2.1 Enzyme toxicity assays are increasingly used in endocrine-disrupting studies—major factor driving market growth
                    TABLE 12 ENZYME TOXICITY ASSAYS: IN VITRO TOXICOLOGY TESTING MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                               TABLE 13 ENZYME TOXICITY ASSAYS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
           7.4.3 CELL-BASED ELISA & WESTERN BLOTS
                    7.4.3.1 Cell-based assays are cost-effective, thereby witnessing increasing adoption in drug discovery
                               TABLE 14 CELL-BASED ELISA & WESTERN BLOTS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                               TABLE 15 CELL-BASED ELISA & WESTERN BLOTS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
           7.4.4 RECEPTOR-BINDING ASSAYS
                    7.4.4.1 Receptor-binding assays are suitable for high-throughput formats, thereby exhibiting accelerated demand
                               TABLE 16 RECEPTOR-BINDING ASSAYS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                               TABLE 17 RECEPTOR-BINDING ASSAYS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
           7.4.5 TISSUE CULTURE ASSAYS
                    7.4.5.1 Tissue culture assays can mimic in-vivo tissue architecture, thereby attracting researchers
                               TABLE 18 TISSUE CULTURE ASSAYS: IN VITRO TOXICOLOGY TESTING MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                               TABLE 19 TISSUE CULTURE ASSAYS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
           7.4.6 OTHER ASSAYS
                    TABLE 20 OTHER ASSAYS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 21 OTHER ASSAYS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    7.5 EQUIPMENT
           7.5.1 FULLY AUTOMATED IN VITRO TOXICOLOGY EQUIPMENT ARE INCREASINGLY ADOPTED IN RESEARCH
                    TABLE 22 EQUIPMENT: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 23 EQUIPMENT: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    7.6 SOFTWARE
           7.6.1 SOFTWARE SOLUTIONS ARE VITAL IN REDUCING ANALYSIS TIME AND MANAGING LARGE VOLUMES OF DATA GENERATED DURING OPERATIONS
                    TABLE 24 SOFTWARE: IN VITRO TOXICOLOGY TESTING MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 25 SOFTWARE: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    7.7 SERVICES
           7.7.1 LACK OF INFRASTRUCTURE AND EXPERTISE HAVE DRIVEN RELIANCE ON SERVICE PROVIDERS
                    TABLE 26 SERVICES: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 27 SERVICES: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)

8 IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICITY ENDPOINT & TEST (Page No. - 103)
    8.1 INTRODUCTION
           FIGURE 23 ORGAN TOXICITY TESTING TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
           TABLE 28 GLOBAL MARKET, BY TOXICITY ENDPOINT & TEST, 2019–2021 (USD MILLION)
           TABLE 29 GLOBAL MARKET, BY TOXICITY ENDPOINT & TEST, 2022–2027 (USD MILLION)
    8.2 ADME (ABSORPTION, DISTRIBUTION, METABOLISM, & EXCRETION)
           8.2.1 ADME TESTING TO COMMAND GLOBAL MARKET DURING FORECAST PERIOD
                    TABLE 30 ADME: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 31 ADME: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    8.3 SKIN IRRITATION, CORROSION, & SENSITIZATION
           8.3.1 SKIN IRRITATION, CORROSION, & SENSITIZATION ARE MAJOR ENDPOINTS STUDIED IN COSMETICS INDUSTRY
                    TABLE 32 SKIN IRRITATION, CORROSION, & SENSITIZATION: IN VITRO TOXICOLOGY TESTING MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 33 SKIN IRRITATION, CORROSION, & SENSITIZATION: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    8.4 GENOTOXICITY
           8.4.1 REGULATORY AUTHORITIES REVIEW AND VALIDATE HIGHER NUMBER OF GENOTOXICITY TESTS THAN ANY OTHER ENDPOINT, THEREBY PROPELLING MARKET GROWTH
                    TABLE 34 GENOTOXICITY: IN VITRO TOXICOLOGY TESTING, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 35 GENOTOXICITY: IN VITRO TOXICOLOGY TESTING, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    8.5 CYTOTOXICITY
           8.5.1 RISING NEED FOR BIOSAFETY LARGELY CONTRIBUTES TO GROWTH OF CYTOTOXICITY TESTING MARKET
                    TABLE 36 CYTOTOXICITY: IN VITRO TOXICOLOGY TESTING MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 37 CYTOTOXICITY: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    8.6 OCULAR TOXICITY TESTING
           8.6.1 IN VITRO AND EX-VIVO METHODS ARE GAINING HIGH RECOGNITION FOR OCULAR TOXICITY TESTING
                    TABLE 38 OCULAR TOXICITY: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 39 OCULAR TOXICITY: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    8.7 ORGAN TOXICITY
           8.7.1 HIGH-CONTENT SCREENING AND CELL-BASED ASSAYS ARE USED TO DETECT ORGAN-SPECIFIC TOXICITY
                    TABLE 40 ORGAN TOXICITY: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 41 ORGAN TOXICITY: TE MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    8.8 PHOTOTOXICITY
           8.8.1 VALIDATED NON-ANIMAL METHODS ARE USED TO EVALUATE PHOTO SAFETY OF COSMETICS, PHARMACEUTICALS, & CHEMICALS
                    TABLE 42 PHOTOTOXICITY: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 43 PHOTOTOXICITY: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    8.9 DERMAL TOXICITY
           8.9.1 IN VITRO METHODS FOR DERMAL TOXICITY TESTING ARE EXPECTED TO GAIN RECOGNITION IN COMING YEARS
                    TABLE 44 DERMAL TOXICITY: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 45 DERMAL TOXICITY: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    8.10 OTHER ENDPOINTS & TESTS
           TABLE 46 OTHER ENDPOINTS & TESTS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
           TABLE 47 OTHER ENDPOINTS & TESTS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)

9 IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY (Page No. - 123)
    9.1 INTRODUCTION
           FIGURE 24 TOXICOGENOMICS SEGMENT TO EXHIBIT HIGHEST CAGR IN  MARKET DURING FORECAST PERIOD
           TABLE 48 GLOBAL MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
           TABLE 49 GLOBAL MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
    9.2 CELL CULTURE
           9.2.1 CELL- & TISSUE-BASED TECHNOLOGIES ARE WIDELY ADOPTED IN IN VITRO TESTING
                    TABLE 50 CELL CULTURE: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 51 CELL CULTURE: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    9.3 HIGH-THROUGHPUT
           9.3.1 INCREASING USE OF HIGH-CONTENT IMAGING TECHNOLOGIES IN TOXICITY TESTING BOOSTS MARKET GROWTH
                    TABLE 52 HIGH-THROUGHPUT: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 53 HIGH-THROUGHPUT: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
    9.4 TOXICOGENOMICS
           9.4.1 IMPROVEMENTS IN PROTEOMIC TECHNOLOGIES ENHANCE STUDY OF GENES & PROTEIN ACTIVITIES DURING TOXICITY ANALYSIS
                    TABLE 54 TOXICOGENOMICS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                    TABLE 55 TOXICOGENOMICS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)

10 IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY (Page No. - 131)
     10.1 INTRODUCTION
               FIGURE 25 PHARMACEUTICALS & BIOPHARMACEUTICALS INDUSTRY TO HOLD LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD
               TABLE 56 GLOBAL MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
               TABLE 57 GLOBAL MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
     10.2 COVID-19 IMPACT, BY INDUSTRY
     10.3 PHARMACEUTICALS & BIOPHARMACEUTICALS
             10.3.1 DRUG ATTRITION RATE LEADS TO HIGH ADOPTION OF IN VITRO TESTING ASSAYS IN EARLY STAGES OF DRUG DEVELOPMENT
                       TABLE 58 PHARMACEUTICALS & BIOPHARMACEUTICALS: GLOBAL MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                       TABLE 59 PHARMACEUTICALS & BIOPHARMACEUTICALS: GLOBAL MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
     10.4 COSMETICS & HOUSEHOLD PRODUCTS
             10.4.1 BAN ON ANIMAL TESTING LEADING TO ADOPTION OF IN VITRO ASSAYS FOR SAFETY TESTING
                       TABLE 60 COSMETICS & HOUSEHOLD PRODUCTS: GLOBAL MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                       TABLE 61 COSMETICS & HOUSEHOLD PRODUCTS: GLOBAL MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
     10.5 FOOD
             10.5.1 INCREASING FOCUS ON FOOD SAFETY DRIVES REQUIREMENT FOR IN VITRO TOXICOLOGY TESTING PRODUCTS
                       TABLE 62 TYPES OF TOXICOLOGY TESTS IN FOOD
                       TABLE 63 FOOD:  MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                       TABLE 64 FOOD: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
     10.6 CHEMICALS
             10.6.1 INCREASING FOCUS ON ORGANOID-BASED IN VITRO APPROACHES FOR CHEMICALS TESTING PROPELS MARKET GROWTH
                       TABLE 65 CHEMICALS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                       TABLE 66 CHEMICALS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)

11 IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD (Page No. - 144)
     11.1 INTRODUCTION
               FIGURE 26 IN-SILICO MODELS TO RECORD HIGHEST CAGR IN MARKET DURING FORECAST PERIOD
               TABLE 67 GLOBAL MARKET, BY METHOD, 2019–2021 (USD MILLION)
               TABLE 68 GLOBAL MARKET, BY METHOD, 2022–2027 (USD MILLION)
     11.2 CELLULAR ASSAYS
             11.2.1 DEVELOPMENT OF MULTI-PARAMETER ASSAYS WILL PROVIDE SIGNIFICANT GROWTH OPPORTUNITIES TO MARKET PLAYERS
                       TABLE 69 CELLULAR ASSAYS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                       TABLE 70 CELLULAR ASSAYS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
     11.3 BIOCHEMICAL ASSAYS
             11.3.1 BIOCHEMICAL ASSAYS ARE ADOPTED AT HIGHER RATE IN PHARMACEUTICALS INDUSTRY THAN CHEMICALS AND FOOD INDUSTRIES
                       TABLE 71 BIOCHEMICAL ASSAYS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                       TABLE 72 BIOCHEMICAL ASSAYS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
     11.4 IN-SILICO MODELS
             11.4.1 IN-SILICO MODELS ARE EXPECTED TO WITNESS HIGHEST CAGR FROM 2022 TO 2027
                       TABLE 73 IN-SILICO MODELS: MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                       TABLE 74 IN-SILICO MODELS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)
     11.5 EX-VIVO MODELS
             11.5.1 EX-VIVO MODELS ARE WIDELY USED IN SKIN AND EYE TOXICOLOGY TESTING IN COSMETICS INDUSTRY
                       TABLE 75 EX-VIVO MODELS: IN VITRO TOXICOLOGY TESTING MARKET, BY GEOGRAPHY, 2019–2021 (USD MILLION)
                       TABLE 76 EX-VIVO MODELS: MARKET, BY GEOGRAPHY, 2022–2027 (USD MILLION)

12 IN VITRO TOXICOLOGY TESTING MARKET, BY GEOGRAPHIC ANALYSIS (Page No. - 155)
     12.1 INTRODUCTION
     12.2 COVID-19 IMPACT, BY REGION
               FIGURE 27 GLOBAL MARKET: GEOGRAPHIC SNAPSHOT
               TABLE 77 GLOBAL MARKET, BY REGION, 2019–2021 (USD MILLION)
               TABLE 78 GLOBAL MARKET, BY REGION, 2022–2027 (USD MILLION)
     12.3 EUROPE
               FIGURE 28 EUROPE: MARKET SNAPSHOT
               TABLE 79 EUROPE: MARKET, BY COUNTRY, 2019–2021 (USD MILLION)
               TABLE 80 EUROPE: MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
               TABLE 81 EUROPE: MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
               TABLE 82 EUROPE: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
               TABLE 83 EUROPE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
               TABLE 84 EUROPE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
               TABLE 85 EUROPE: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
               TABLE 86 EUROPE: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
               TABLE 87 EUROPE: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
               TABLE 88 EUROPE: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
               TABLE 89 EUROPE: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
               TABLE 90 EUROPE: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
               TABLE 91 EUROPE: MARKET, BY METHOD, 2019–2021 (USD MILLION)
               TABLE 92 EUROPE: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.3.1 GERMANY
                       12.3.1.1 Germany holds the largest share of the European market
                                   TABLE 93 GERMANY: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 94 GERMANY: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 95 GERMANY: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE,  2019–2021 (USD MILLION)
                                   TABLE 96 GERMANY: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                                   TABLE 97 GERMANY: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 98 GERMANY: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 99 GERMANY: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 100 GERMANY: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                   TABLE 101 GERMANY: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                                   TABLE 102 GERMANY: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 103 GERMANY: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 104 GERMANY: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.3.2 UK
                       12.3.2.1 Rising awareness, growing R&D, and increasing collaborations for In Vitro Toxicology Testing Market are key indicators of market growth in UK
                                   TABLE 105 UK: MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 106 UK: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 107 UK: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                                   TABLE 108 UK: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022-2027 (USD MILLION)
                                   TABLE 109 UK: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 110 UK: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 111 UK: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 112 UK: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                   TABLE 113 UK: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                                   TABLE 114 UK: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 115 UK: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 116 UK: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.3.3 FRANCE
                       12.3.3.1 Proteomics research initiatives supported by government aid market growth in France
                                   TABLE 117 FRANCE: MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 118 FRANCE: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 119 FRANCE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE,  2019–2021 (USD MILLION)
                                   TABLE 120 FRANCE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                                   TABLE 121 FRANCE: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 122 FRANCE: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 123 FRANCE: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 124 FRANCE: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                   TABLE 125 FRANCE: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                                   TABLE 126 FRANCE: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 127 FRANCE: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 128 FRANCE: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.3.4 ITALY
                       12.3.4.1 Italian market growth is mainly driven by increased volume of life sciences research
                                   TABLE 129 ITALY: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 130 ITALY: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 131 ITALY: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                                   TABLE 132 ITALY: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                                   TABLE 133 ITALY: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 134 ITALY: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 135 ITALY: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 136 ITALY: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                   TABLE 137 ITALY: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                                   TABLE 138 ITALY: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 139 ITALY: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 140 ITALY: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.3.5 SPAIN
                       12.3.5.1 Spain’s growing Chemicals industry stimulates in vitro toxicology testing market growth
                                   TABLE 141 SPAIN: MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 142 SPAIN: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 143 SPAIN: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                                   TABLE 144 SPAIN: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                                   TABLE 145 SPAIN: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 146 SPAIN: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 147 SPAIN: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 148 SPAIN: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                   TABLE 149 SPAIN: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                                   TABLE 150 SPAIN: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 151 SPAIN: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 152 SPAIN: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.3.6 REST OF EUROPE
                       TABLE 153 REST OF EUROPE: MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                       TABLE 154 REST OF EUROPE: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                       TABLE 155 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                       TABLE 156 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                       TABLE 157 REST OF EUROPE: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                       TABLE 158 REST OF EUROPE: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                       TABLE 159 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                       TABLE 160 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                       TABLE 161 REST OF EUROPE: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                       TABLE 162 REST OF EUROPE: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                       TABLE 163 REST OF EUROPE: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                       TABLE 164 REST OF EUROPE: MARKET, BY METHOD, 2022–2027 (USD MILLION)
     12.4 NORTH AMERICA
               FIGURE 29 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET SNAPSHOT
               TABLE 165 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2021 (USD MILLION)
               TABLE 166 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
               TABLE 167 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
               TABLE 168 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
               TABLE 169 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
               TABLE 170 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
               TABLE 171 NORTH AMERICA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
               TABLE 172 NORTH AMERICA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
               TABLE 173 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
               TABLE 174 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
               TABLE 175 NORTH AMERICA: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
               TABLE 176 NORTH AMERICA: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
               TABLE 177 NORTH AMERICA: MARKET, BY METHOD, 2019–2021 (USD MILLION)
               TABLE 178 NORTH AMERICA: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.4.1 US
                       12.4.1.1 US dominates North American market due to growing focus on biomarker discovery and research in structure-based drug design
                                   TABLE 179 US: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 180 US: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 181 US: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                                   TABLE 182 US: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                                   TABLE 183 US: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 184 US: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 185 US: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 186 US: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                   TABLE 187 US: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                                   TABLE 188 US: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 189 US: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 190 US: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.4.2 CANADA
                       12.4.2.1 Strong support to carry out R&D in pharmaceutical and proteomics fields fosters market growth in Canada
                                   TABLE 191 CANADA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 192 CANADA: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 193 CANADA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                                   TABLE 194 CANADA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                                   TABLE 195 CANADA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 196 CANADA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 197 CANADA: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 198 CANADA: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                   TABLE 199 CANADA: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                                   TABLE 200 CANADA: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 201 CANADA: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 202 CANADA: MARKET, BY METHOD, 2022–2027 (USD MILLION)
     12.5 ASIA PACIFIC
               FIGURE 30 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET SNAPSHOT
               TABLE 203 ASIA PACIFIC:MARKET, BY COUNTRY, 2019–2021 (USD MILLION)
               TABLE 204 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
               TABLE 205 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
               TABLE 206 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
               TABLE 207 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
               TABLE 208 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
               TABLE 209 ASIA PACIFIC: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
               TABLE 210 ASIA PACIFIC: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
               TABLE 211 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
               TABLE 212 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
               TABLE 213 ASIA PACIFIC: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
               TABLE 214 ASIA PACIFIC: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
               TABLE 215 ASIA PACIFIC: MARKET, BY METHOD, 2019–2021 (USD MILLION)
               TABLE 216 ASIA PACIFIC: MARKET, BY METHOD,  2022–2027 (USD MILLION)
             12.5.1 CHINA
                       12.5.1.1 Increasing international pressure to ban animal testing methods will propel market growth in coming years
                                   TABLE 217 CHINA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 218 CHINA: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 219 CHINA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                                   TABLE 220 CHINA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                                   TABLE 221 CHINA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 222 CHINA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 223 CHINA: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 224 CHINA: MARKET, BY TECHNOLOGY,  2022–2027 (USD MILLION)
                                   TABLE 225 CHINA: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                                   TABLE 226 CHINA: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 227 CHINA: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 228 CHINA: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.5.2 JAPAN
                       12.5.2.1 Use of artificial skin patches and plates of cultured human cells has increased demand for in vitro toxicology testing products in Japan
                                   TABLE 229 JAPAN: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 230 JAPAN: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 231 JAPAN: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                                   TABLE 232 JAPAN: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                                   TABLE 233 JAPAN: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 234 JAPAN: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 235 JAPAN: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 236 JAPAN: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                   TABLE 237 JAPAN: MARKET, BY INDUSTRY,  2019–2021 (USD MILLION)
                                   TABLE 238 JAPAN: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 239 JAPAN: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 240 JAPAN: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.5.3 INDIA
                       12.5.3.1 Growing focus of universities on avoiding use of animals to test cosmetic products is likely to propel market growth
                                   TABLE 241 INDIA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                                   TABLE 242 INDIA: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                                   TABLE 243 INDIA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                                   TABLE 244 INDIA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                                   TABLE 245 INDIA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                                   TABLE 246 INDIA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                                   TABLE 247 INDIA: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                                   TABLE 248 INDIA: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                   TABLE 249 INDIA: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                                   TABLE 250 INDIA: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                                   TABLE 251 INDIA: IN VITRO TRO TOXICOLOGY TESTING MARKET, BY METHOD, 2019–2021 (USD MILLION)
                                   TABLE 252 INDIA: MARKET, BY METHOD, 2022–2027 (USD MILLION)
             12.5.4 REST OF ASIA PACIFIC
                       TABLE 253 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                       TABLE 254 REST OF ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                       TABLE 255 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                       TABLE 256 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                       TABLE 257 REST OF ASIA PACIFIC: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                       TABLE 258 REST OF ASIA PACIFIC: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                       TABLE 259 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                       TABLE 260 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                       TABLE 261 REST OF ASIA PACIFIC: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                       TABLE 262 REST OF ASIA PACIFIC: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                       TABLE 263 REST OF ASIA PACIFIC: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                       TABLE 264 REST OF ASIA PACIFIC: MARKET, BY METHOD, 2022–2027 (USD MILLION)
     12.6 LATIN AMERICA
             12.6.1 LOW COST OF DRUG TRIALS HAVE MADE LATIN AMERICA POPULAR OUTSOURCING MARKET
                       TABLE 265 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                       TABLE 266 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                       TABLE 267 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                       TABLE 268 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                       TABLE 269 LATIN AMERICA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                       TABLE 270 LATIN AMERICA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                       TABLE 271 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                       TABLE 272 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                       TABLE 273 LATIN AMERICA: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                       TABLE 274 LATIN AMERICA: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                       TABLE 275 LATIN AMERICA: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                       TABLE 276 LATIN AMERICA: MARKET, BY METHOD, 2022–2027 (USD MILLION)
     12.7 MIDDLE EAST & AFRICA
             12.7.1 INCREASING R&D INVESTMENTS AND FOCUS ON DEVELOPMENT OF NEW DRUGS ARE CONTRIBUTING TO MARKET GROWTH
                       TABLE 277 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2019–2021 (USD MILLION)
                       TABLE 278 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2022–2027 (USD MILLION)
                       TABLE 279 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2019–2021 (USD MILLION)
                       TABLE 280 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2022–2027 (USD MILLION)
                       TABLE 281 MIDDLE EAST & AFRICA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2019–2021 (USD MILLION)
                       TABLE 282 MIDDLE EAST & AFRICA: MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2022–2027 (USD MILLION)
                       TABLE 283 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2019–2021 (USD MILLION)
                       TABLE 284 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                       TABLE 285 MIDDLE EAST & AFRICA: MARKET, BY INDUSTRY, 2019–2021 (USD MILLION)
                       TABLE 286 MIDDLE EAST & AFRICA: MARKET, BY INDUSTRY, 2022–2027 (USD MILLION)
                       TABLE 287 MIDDLE EAST & AFRICA: MARKET, BY METHOD, 2019–2021 (USD MILLION)
                       TABLE 288 MIDDLE EAST & AFRICA: MARKET, BY METHOD, 2022–2027 (USD MILLION)

13 COMPETITIVE LANDSCAPE (Page No. - 264)
     13.1 OVERVIEW
     13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
               FIGURE 31 KEY DEVELOPMENTS IN IN VITRO TOXICOLOGY TESTING MARKET, 2019–2022
     13.3 MARKET SHARE ANALYSIS
               FIGURE 32 GLOBAL MARKET SHARE, BY KEY PLAYER, 2021
               TABLE 289 GLOBAL MARKET: DEGREE OF COMPETITION
     13.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
     13.5 COMPANY EVALUATION QUADRANT
             13.5.1 STAR
             13.5.2 EMERGING LEADER
             13.5.3 PERVASIVE
             13.5.4 PARTICIPANT
                       FIGURE 34 IN VITRO TOXICOLOGY TESTING MARKET: COMPANY EVALUATION QUADRANT, 2021
     13.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
             13.6.1 PROGRESSIVE COMPANY
             13.6.2 STARTING BLOCK
             13.6.3 RESPONSIVE COMPANY
             13.6.4 DYNAMIC COMPANY
                       FIGURE 35 IN VITRO TOXICITY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021
     13.7 COMPANY FOOTPRINT ANALYSIS
             13.7.1 COMPANY PRODUCT FOOTPRINT
                       TABLE 290 COMPANY PRODUCT FOOTPRINT: IN VITRO TOXICOLOGY TESTING MARKET (2021)
     13.8 COMPANY REGIONAL FOOTPRINT
               TABLE 291 COMPANY REGIONAL FOOTPRINT: GLOBAL MARKET (2021)
     13.9 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
               TABLE 292 GLOBAL MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
               TABLE 293 GLOBAL MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
     13.10 COMPETITIVE SCENARIO
               TABLE 294 PRODUCT LAUNCHES
               TABLE 295 DEALS
            TABLE 296 OTHER DEVELOPMENTS

14 COMPANY PROFILES (Page No. - 278)
     14.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             14.1.1 THERMO FISHER SCIENTIFIC, INC.
                       TABLE 297 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                       FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             14.1.2 MERCK KGAA
                       TABLE 298 MERCK KGAA: BUSINESS OVERVIEW
                       FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2021)
             14.1.3 EUROFINS SCIENTIFIC SE
                       TABLE 299 EUROFINS SCIENTIFIC SE: BUSINESS OVERVIEW
                       FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
             14.1.4 GENERAL ELECTRIC COMPANY
                       TABLE 300 GENERAL ELECTRIC COMPANY: BUSINESS OVERVIEW
                       FIGURE 39 GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT (2021)
             14.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
                       TABLE 301 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
                       FIGURE 40 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
             14.1.6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                       TABLE 302 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
                       FIGURE 41 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
             14.1.7 SGS SA
                       TABLE 303 SGS SA: BUSINESS OVERVIEW
                       FIGURE 42 SGS SA: COMPANY SNAPSHOT (2021)
             14.1.8 BIO-RAD LABORATORIES, INC.
                       TABLE 304 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                       FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             14.1.9 QIAGEN
                       TABLE 305 QIAGEN: BUSINESS OVERVIEW
                       FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2021)
             14.1.10 EVOTEC AG
                       TABLE 306 EVOTEC AG: BUSINESS OVERVIEW
                       FIGURE 45 EVOTEC AG: COMPANY SNAPSHOT (2021)
             14.1.11 PROMEGA CORPORATION
                       TABLE 307 PROMEGA CORPORATION.: BUSINESS OVERVIEW
             14.1.12 CATALENT, INC.
                       TABLE 308 CATALENT, INC.: BUSINESS OVERVIEW
                       FIGURE 46 CATALENT, INC.: COMPANY SNAPSHOT (2021)
     14.2 OTHER COMPANIES
             14.2.1 GENTRONIX LIMITED
                       TABLE 309 GENTRONIX LIMITED: COMPANY OVERVIEW
             14.2.2 MB RESEARCH LABORATORIES
                       TABLE 310 MB RESEARCH LABORATORIES: COMPANY OVERVIEW
             14.2.3 BIOIVT
                       TABLE 311 BIOIVT: COMPANY OVERVIEW
             14.2.4 CREATIVE BIOLABS
                       TABLE 312 CREATIVE BIOLABS: COMPANY OVERVIEW
             14.2.5 GVK BIOSCIENCES PRIVATE LIMITED
                       TABLE 313 GVK BIOSCIENCES PRIVATE LIMITED: COMPANY OVERVIEW
             14.2.6 SHANGHAI MEDICILON INC.
                       TABLE 314 SHANGHAI MEDICILON INC.: COMPANY OVERVIEW
             14.2.7 CREATIVE BIOARRAY
                       TABLE 315 CREATIVE BIOARRAY: COMPANY OVERVIEW
             14.2.8 INSPHERO
                       TABLE 316 INSPHERO: COMPANY OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 RELATED MARKETS (Page No. - 345)
     15.1 INTRODUCTION
     15.2 IN VIVO TOXICITY MARKET
             15.2.1 MARKET DEFINITION
             15.2.2 LIMITATIONS
             15.2.3 MARKET OVERVIEW
                       FIGURE 47 CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE IN VIVO TOXICOLOGY MARKET DURING THE FORECAST PERIOD
     15.3 IN VIVO TOXICOLOGY MARKET, BY PRODUCT
             15.3.1 CONSUMABLES
                       TABLE 317 IN VIVO TOXICITY CONSUMABLES MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
             15.3.2 INSTRUMENTS
                       TABLE 318 IN VIVO TOXICOLOGY INSTRUMENTS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
     15.4 IN VIVO TOXICITY MARKET, BY TOXICITY ENDPOINT
             15.4.1 IMMUNOTOXICITY
                       TABLE 319 IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
             15.4.2 SYSTEMIC TOXICITY
                       TABLE 320 IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
             15.4.3 CARCINOGENICITY
                       TABLE 321 IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
             15.4.4 GENOTOXICITY
                       TABLE 322 IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
             15.4.5 DEVELOPMENTAL AND REPRODUCTIVE TOXICITY (DART)
                       TABLE 323 IN VIVO TOXICOLOGY MARKET FOR DEVELOPMENTAL AND REPRODUCTIVE TOXICITY, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
             15.4.6 OTHER TOXICITY ENDPOINTS
                       TABLE 324 IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
     15.5 IN VIVO TOXICITY MARKET, BY REGION
             15.5.1 NORTH AMERICA
                       TABLE 325 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TOXICOLOGY ENDPOINT, 2015–2022 (USD MILLION)
             15.5.2 EUROPE
                       TABLE 326 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TOXICOLOGY ENDPOINT, 2015–2022 (USD MILLION)
             15.5.3 ASIA PACIFICASIA PACIFIC
                       TABLE 327 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY TOXICOLOGY ENDPOINT, 2015–2022 (USD MILLION)
             15.5.4 LATIN AMERICA
                       TABLE 328 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TOXICOLOGY ENDPOINT, 2015–2022 (USD MILLION)
             15.5.5 MIDDLE EAST & AFRICA
                       TABLE 329 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TOXICOLOGY ENDPOINT, 2015–2022 (USD MILLION)

16 APPENDIX (Page No. - 360)
     16.1 INSIGHTS OF INDUSTRY EXPERTS
     16.2 DISCUSSION GUIDE
     16.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     16.4 AVAILABLE CUSTOMIZATIONS
     16.5 RELATED REPORTS
     16.6 AUTHOR DETAILS

In this report, the global market for in vitro toxicology testing was arrived at after data triangulation from two different approaches as mentioned below. After completion of each approach, a weighted average of the two approaches was taken on the basis of the level of assumptions used in each approach.

Secondary Research

This research study involved the use of widespread secondary sources; directories; databases such as Factiva, Dun & Bradstreet, and Bloomberg Businessweek; white papers; annual reports; and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the global in vitro toxicity testing market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, key developments related to market, and technology perspectives.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the in vitro toxicology testing market. Primary sources from the demand side include scientists/researchers from academic & research institutes and government & private laboratories.

Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics. A breakdown of the primary respondents is provided below:

In Vitro Toxicology Testing Market   Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by product and service segment along with the technology, toxicity endpoint & tests, industry, method, and region).

Data Triangulation

After arriving at the market size, the total in vitro toxicology testing market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, segment, and forecast the global in vitro toxicology testing market by product & service, technology, toxicity endpoint & test, industry, method, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall in vitro toxicology testing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To profile key players in the global in vitro toxicology testing market and comprehensively analyze their core competencies and market shares
  • To forecast the size of the in vitro toxicology testing market in five main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To benchmark players within the in vitro toxicology testing market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
  • To track and analyze competitive developments, such as acquisitions, new product launches, expansions, collaborations, and R&D activities of the leading players in the in vitro toxicology testing market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific in vitro toxicology testing market into South Korea, Australia, New Zealand, and others
  • Further breakdown of the Rest of Europe in vitro toxicology testing market into Switzerland, Belgium, Russia, the Netherlands, and others
In Vitro Toxicology Testing Market Size,  Share & Growth Report
Report Code
BT 2373
Published ON
Jun, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status